Q-omics provides the consensus-scored TDRD9 profile across patient tissues and cancer cell-line models. TDRD9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TDRD9 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TDRD9 RNA expression shows 14,727 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, THCA, and TGCT as cancer lineages where TDRD9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TDRD9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TDRD9 survival associations across molecular data types. TDRD9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TDRD9 RNA expression–survival associations across cancer types. High TDRD9 expression shows unfavorable associations in MESO and ESCA, but favorable associations in ACC, LAML, PAAD and OV. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TDRD9 RNA expression.
This table summarizes TDRD9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TDRD9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TDRD9 shows lower tumor expression in THCA, KICH, LUSC, KIRC and KIRP and higher tumor expression in HNSC. The THCA box plot shows higher TDRD9 RNA expression in normal versus tumor tissue (log2 FC = −3.717, t-test p < 0.001).
This table shows molecular features associated with TDRD9 in patient tissues and cancer cell lines. In patient samples, TDRD9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TDRD9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
